For the study, published Dec. 6 in JAMA Network Open, researchers at the Chinese University of Hong Kong analyzed the outcomes of 12,629 adult COVID-19 patients hospitalized between Jan. 1 and March 31, when the omicron variant was dominant. Of these patients, 195 received Paxlovid, 746 received molnupiravir and 11,688 were not treated with an antiviral.
One percent of Paxlovid recipients had a viral rebound, compared to 0.8 percent of molnupiravir recipients and 0.6 percent of people who didn’t receive antivirals.
“In this study, viral rebound was uncommon in adults with COVID-19 after treatment with nirmatrelvir-ritonavir and molnupiravir, suggesting that these novel oral antivirals should be prescribed to more patients with COVID-19 in the early phase of the infection,” study authors wrote.
View the full study here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.